Trials / Completed
CompletedNCT01589133
Surgiscreen Registration
A Multi-center Clinical Study for Assessment of the Consistency of the Results of Human Irregular Antibody Screening With Surgiscreen and Serascan Diana 3
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,109 (actual)
- Sponsor
- Johnson & Johnson Medical, China · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the consistency of the results of irregular antibody screening with Surgiscreen （investigational reagent) and Serascan Diana 3 (control reagent), and the consistency of the results of irregular antibody screening with investigational reagent on serum and plasma from same patients.
Conditions
Timeline
- Start date
- 2012-05-01
- Primary completion
- 2012-10-01
- Completion
- 2012-10-01
- First posted
- 2012-05-01
- Last updated
- 2013-05-30
Locations
4 sites across 1 country: China
Source: ClinicalTrials.gov record NCT01589133. Inclusion in this directory is not an endorsement.